The Human Retroviruses¶
Part 5: Infectious Diseases | Part 5 – Infectious Diseases: Viral (incl. HIV) · Part 5 – Infectious Diseases: Viral (incl. HIV) · Chapter 207
Key Clinical Points¶
- Retroviruses replicate via RNA → DNA conversion using reverse transcriptase, creating a provirus integrated into the host genome.
- HTLV-1 is a deltaretrovirus causing Adult T-cell Leukemia/Lymphoma (ATL) and HTLV-1-associated myelopathy (HAM).
- ATL presents in four clinical types: acute, lymphomatous, chronic, and smoldering, each with distinct prognoses.
- HAM is a progressive myelopathy resembling multiple sclerosis, disproportionately affecting women.
- HTLV-1 transmission occurs via breast milk, sexual contact (male → female predominance), and blood products/needle sharing.
- Diagnosis of HTLV-1 infection requires serology (ELISA) followed by confirmatory testing (Western blot or PCR).
- ATL diagnosis relies on flow cytometry (CD4+/CD3+/CD25+) and molecular testing for clonal TCR gene rearrangements.
- HAM is confirmed via MRI showing white matter/spinal cord lesions and CSF antibody titers exceeding serum levels.
- Treatment for ATL involves VCAP-AMP-VECP chemotherapy, while HAM has no curative treatment (symptomatic management).
- Endogenous retroviral sequences in the human genome are not replication-competent.
- Prevention focuses on blood donor screening and avoiding breastfeeding in endemic regions.
- Lentiviral vectors used in gene therapy carry risks of insertional mutagenesis and viral reactivation.
1. DEFINITION & CLASSIFICATION¶
Retroviruses belong to the family Retroviridae, characterized by RNA → DNA conversion via reverse transcriptase.
Key Features:
• Unique replication cycle: Involves proviral integration into host DNA • Host gene alteration: Ability to alter host gene expression through insertion near cellular genes • Clinical impact: Role in both oncogenesis (e.g., HTLV-1) and immunodeficiency (e.g., HIV) • Gene therapy: Used as vectors in gene therapy despite risks of insertional mutagenesis• Classification: Includes deltaretroviruses (HTLV-1) and lentiviruses (HIV)
1.1 Classification of Retroviruses¶
The family Retroviridae comprises several subfamilies, with two clinically significant groups:
• Deltaretroviruses: HTLV-1 causes ATL and HAM • Lentiviruses: HIV causes AIDS
Table 207-1 provides the classification framework for various retroviral genera.
2. EPIDEMIOLOGY¶
HTLV-1 transmission occurs via several routes:
• Mother-to-child: Primarily through breast milk • Sexual contact: Showing a male → female predominance • Blood products: Including blood transfusions and needle sharing
Endemic Regions & Prevalence:
• High prevalence areas: Southwestern Japan (>1 million infected), Okinawa (35% seroprevalence), Brazil, Africa, and the Caribbean • Global estimates: 10–20 million individuals infected • Clinical observation: Only ~500 ATL cases/year are reported in Japan despite high infection rates.
3. ETIOLOGY & PATHOPHYSIOLOGY¶
HTLV-1 pathogenesis is driven by specific viral proteins and integration dynamics:
• Tax protein: • Induces host gene expression (NF-κB, IL-2, MHC) • Disrupts cell cycle checkpoints • HBZ protein: • Maintains transformed state in ATL cells • Functions as an anti-apoptotic factor • Proviral Integration: • Occurs at random sites • Latency for ATL: 20–30 years • Latency for HAM: ~3.3 years
Mechanisms of Disease:
• Oncogenesis: Via Tax-induced clonal T-cell proliferation • Autoimmune Myelopathy (HAM): Through viral antigen-specific T-cell responses • Immunodeficiency: State similar to AIDS
3.1 HTLV-1 Biology and Molecular Biology¶
Structure and function of the HTLV-1 virion:
• Physical Properties: 70–130 nm virion with lipid envelope and RNA genome (8–10 kb) • Core Genes: gag (capsid), pol (reverse transcriptase/integrase), env (surface receptors) • Regulatory Proteins: Tax (transcription activation), Rex (mRNA regulation), HBZ (anti-apoptotic) • Receptor Complex: Includes GLUT-1, NRP1, and heparan sulfate proteoglycans
Figure 207-1 illustrates the replication cycle including reverse transcription and integration. Figure 207-2 shows the genomic structure of various retroviruses, highlighting the difference in accessory proteins between HTLV-1 and HIV.
4. CLINICAL FEATURES¶
HTLV-1 manifests primarily as ATL or HAM.
ATL (4 clinical types):
• Acute: Rapid progression, skin lesions, hypercalcemia, lymphocytosis with 'flower-shaped' nuclei • Lymphomatous: Similar to acute but with lymphadenopathy • Chronic: Indolent course with low-grade symptoms • Smoldering: Indolent course with low-grade symptoms
HAM (HTLV-1 associated myelopathy):
• Clinical Presentation: Progressive spastic paraparesis (similar to multiple sclerosis) • Imaging: MRI shows white matter and spinal cord lesions • CSF Findings: Elevated HTLV-1 antibodies; 50% of cases have normal protein levels
4.1 Acute ATL¶
Clinical presentation of the acute form:
• Median survival: 6 months • Skin lesions: Often difficult to distinguish from mycosis fungoides • Hypercalcemia: Due to osteoclast-activating factors • Bone involvement: Lytic bone lesions without tumor cells • Opportunistic infections: Pneumocystis, Strongyloides stercoralis
5. DIFFERENTIAL DIAGNOSIS¶
Differential diagnosis for HAM includes:
• Multiple sclerosis (MS): Similar spasticity and MRI findings • Other autoimmune myelopathies
Note: HTLV-1-associated dermatitis, uveitis, and arthritis have no definitive causal link established.
6. DIAGNOSTIC APPROACH¶
The diagnostic sequence for HTLV-1 associated conditions is as follows:
- Initial Screening: Perform anti-HTLV-1 ELISA in serum or CSF
- Confirmatory Testing: Follow with Western blot or PCR for viral DNA
- HAM Confirmation: • MRI to identify white matter/spinal cord lesions • CSF analysis: Confirm elevated HTLV-1 antibody titers > serum levels
- ATL Diagnosis: • Flow cytometry: Identify CD4+/CD3+/CD25+ lymphocytes • Molecular testing: Detect clonal TCR gene rearrangements • Bone marrow biopsy: Assess for patchy involvement
7. MANAGEMENT & TREATMENT¶
Treatment strategies vary by clinical presentation:
ATL Management: 1. Initial Assessment: Stage the disease (acute, lymphomatous, chronic, smoldering) 2. First-line Therapy: VCAP-AMP-VECP chemotherapy (6 cycles) 3. Evaluation: Assess response after 4 cycles 4. Second-line/Relapse: Interferon-alpha or AZT (azidothymidine) 5. Advanced Options: Allogeneic stem cell transplantation in selected cases
HAM Management: 1. No curative treatment available 2. Symptomatic management with corticosteroids and physical therapy
7.1 ATLL Management Decision Tree (Figure 207-5)¶
The following decision tree determines the treatment path for ATLL based on staging:
1. Smoldering Pathway: • Criteria: ≤ 80% atypical T cells/μL; ≤ 10% lymphocytes/μL; and LDH ≤ 1.5 imes upper limit of normal (ULN) • Asymptomatic or Symptomatic: - Option A: IFN α and AZT-based therapy - Option B: Chemotherapy with or without topical steroids - If progression occurs → move to "more intense therapies and approaches"
2. Chronic Pathway: • Criteria: >3% atypical1 atypical T cells/μL; >10% lymphocytes/μL; and LDH >1.5 imes ULN • Favourable: IFN α and AZT-based therapy (with or without AZT) continued indefinitely• Unfavourable: - Option A: IFN α and AZT-based therapy (if preferred) - Option B: Chemotherapy followed by allogeneic HSCT
3. Lymphoma Pathway: • Criteria: ≤ 10% lymphocytes/μL, confirmed by histology • Extranodal primary cutaneous variant: - Action: Intensive chemotherapy • Other Lymphoma types: - If "Early-up, allogeneic HSCT" available → Concurrent chemo/AZT-based therapy (non-dose-free) OR AZT-based therapy - If not available or bulky disease → Intensive chemotherapy
4. Acute Pathway: • Criteria: All remaining cases with clinical manifestations not classified as Smoldering, Chronic, or Lymphoma • If IFN α and AZT-based therapy preferred: Use if no bulky disease• If no preference/bulky disease: Intensive chemotherapy
Note on Transplant: If "Early-up, allogeneic HSCT" is available, it can be utilized for both Lymphoma and Acute cases.
8. COMPLICATIONS & PROGNOSIS¶
Prognostic outcomes vary significantly by clinical stage (Figure 207-5):
• Smoldering: 4+ year survival ≥ 80%; Median survival 55 months • Chronic: 4+ year survival ≥ 30%; Median survival 35 months • Lymphoma: 4+ year survival ≥ 16%; Median survival 66 months • Acute: 4+ year survival ≥ 8; Median survival 30 months
Complications:
• Opportunistic infections (Pneumocystis, Strongyloides) • Hypercalcemia-related complications • Progressive neurological deterioration in HAM
9. SPECIAL CONSIDERATIONS¶
Public health and prevention strategies:
• Blood Safety: Universal screening of blood donors for HTLV-1 • Maternal Health: Education on avoiding breastfeeding in endemic regions • Sexual Health: Targeted education for high-risk populations
Gene Therapy Considerations:
• Use of Lentiviral vectors for genetic correction • Risks: Insertional mutagenesis and replication-competent virus reactivation.
10. KEY PEARLS & CLINICAL TRAPS¶
Clinical Pearls:
• Endogenous Retroviruses: These are not replication-competent in the human genome. • HAM Presentation: May present with bladder dysfunction in women without neurological symptoms. • Morphology: ATL skin lesions resemble mycosis fungoides but lack epidermotropism.
Common Pitfalls:
• Confusing chronic ATL with other T-cell lymphomas. • Overlooking HTLV-1 as a cause of spastic paraparesis. • Misinterpreting normal CSF protein levels in cases of ATL with CNS involvement.
Reference Tables¶
TABLE 207-1 Classification of Retroviruses: The Family Retroviridae GENUS Alpharetrovirus Betaretrovirus…¶
Harrison's 22e, p.1550
| GENUS | EXAMPLE(S) | FEATURE |
|---|---|---|
| Alpharetrovirus | Rous sarcoma virus | Contains src oncogene |
| Mouse mammary tumor virus | ||
| Gammaretrovirus | Abelson murine leukemia virus | Contains abl oncogene |
| HTLV-1 | ||
| Epsilonretrovirus | Walleye dermal sarcoma virus | Not known to be pathogenic in humans |
| HIV-1, HIV-2 | ||
| Spumavirus | Simian foamy virus | Not known to be pathogenic in humans |